Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Intellia Therapeutics Inc shares valued at $1,003,000 were purchased by CHASE WILLIAM J on Aug 20 ’25. At $10.03 per share, CHASE WILLIAM J acquired 100,000 shares. The insider’s holdings grew to 134,693 shares worth approximately $2.75 million following the completion of this transaction.
Also, Dulac Edward J III sold 7,462 shares, netting a total of over 104,617 in proceeds. Following the sale of shares at $14.02 each, the insider now holds 106,062 shares.
Before that, Clark Eliana had sold 1,022 shares from its account. In a trade valued at $10,036, the EVP, Chief Technical Officer traded Intellia Therapeutics Inc shares for $9.82 each. Upon closing the transaction, the insider’s holdings decreased to 1,022 shares, worth approximately $1.95 million.
As published in a research note from Wolfe Research on April 21, 2025, Intellia Therapeutics Inc [NTLA] has been rated up from a Peer perform to an Outperform and the price target has been revised to $21. Analysts at H.C. Wainwright started covering the stock with ‘”a Buy”‘ outlook in a report released in early March. As of February 28, 2025, JP Morgan has decreased its “an Overweight” rating to a “Neutral” for NTLA. Earlier on February 28, 2025, Goldman downgraded its rating. Their new recommendation was “a Sell” for NTLA stock which previously was a “a Neutral”.
Analyzing NTLA Stock Performance
On last trading session, Intellia Therapeutics Inc [NASDAQ: NTLA] rose 8.96% to $20.44. The stock’s lowest price that day was $18.92, but it reached a high of $20.585 in the same session. During the last five days, there has been a surge of approximately 23.06%. Over the course of the year, Intellia Therapeutics Inc shares have dropped approximately -0.54%. Shares of the company reached a 52-week high of $20.58 on 10/02/25 and a 52-week low of $5.90 on 04/07/25.
Support And Resistance Levels for Intellia Therapeutics Inc (NTLA)
According to the 24-hour chart, there is a support level at 19.38, which, if violated, would cause prices to drop to 18.32. In the upper region, resistance lies at 21.04. The next price resistance is at 21.65. RSI (Relative Strength Index) is 79.89 on the 14-day chart, showing overbought technical sentiment.
Is Intellia Therapeutics Inc subject to short interest?
Stocks of Intellia Therapeutics Inc saw a sharp rise in short interest on 2025-09-15 jumping by 6.41 million shares to 34.14 million. Data from Yahoo Finance shows that the short interest on 2025-08-15 was 27.73 million shares. A jump of 18.77% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 8.38 of the overall float, the days-to-cover ratio (short ratio) jumped to 8.38.
Which companies own the most shares of Intellia Therapeutics Inc (NTLA)?
In terms of Intellia Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 14 in the next 12 months, down nearly -25.37% from the previous closing price of $18.76. Analysts anticipate Intellia Therapeutics Inc stock to reach 14 by 2025, with the lowest price target being 14. In spite of this, 13 analysts ranked Intellia Therapeutics Inc stock as Buy at the end of 2025. On January 27, 2025, Morgan Stanley assigned a price target of “an Equal-weight” to the stock and downgraded coverage with a $11.
